FOXO1 mediates Vitamin D deficiency-induced insulin resistance in skeletal muscle

Journal of Bone and Mineral Research

Volumn 31, Issue 3, 2016, Pages 585-595

  Chen, Songcang ^a   Villalta, S Armando ^b   Agrawal, Devendra K ^a  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

FOXO1; GENE DELETION; INSULIN RESISTANCE; SKELETAL MUSCLE; Vitamin D

Indexed keywords

CALCITRIOL; CD36 ANTIGEN; GLUCOSE; GLUCOSE TRANSPORTER 4; INSULIN; INSULIN RECEPTOR; INSULIN RECEPTOR SUBSTRATE 1; INSULIN RECEPTOR SUBSTRATE 2; LIPOPROTEIN LIPASE; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN KINASE B BETA; SOMATOMEDIN C; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR FKHR; TRANSCRIPTION FACTOR FKHRL1; TRANSCRIPTION FACTOR FOXO; TRANSCRIPTION FACTOR FOXO4; UNCLASSIFIED DRUG; VITAMIN D; VITAMIN D RECEPTOR; CALCITRIOL RECEPTOR; COLECALCIFEROL; FOXO1 PROTEIN, MOUSE;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FEMALE; GENE SILENCING; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; GLUCOSE METABOLISM; INSULIN RESISTANCE; MOLECULAR PATHOLOGY; MOUSE; MYOBLAST; MYOTUBE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; TRANSCRIPTION INITIATION; VITAMIN D DEFICIENCY; ANIMAL; ANTIBODY SPECIFICITY; CELL LINE; CELL NUCLEUS; DEFICIENCY; GENE DELETION; GENE EXPRESSION REGULATION; MALE; METABOLISM; PATHOLOGY; PROTEIN TRANSPORT; SKELETAL MUSCLE CELL;

ANIMALS; CELL LINE; CELL NUCLEUS; CHOLECALCIFEROL; FEMALE; FORKHEAD BOX PROTEIN O1; GENE DELETION; GENE EXPRESSION REGULATION; GLUCOSE; INSULIN RESISTANCE; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MALE; MICE; MUSCLE FIBERS, SKELETAL; MUSCLE, SKELETAL; ORGAN SPECIFICITY; PROTEIN TRANSPORT; RECEPTORS, CALCITRIOL; VITAMIN D DEFICIENCY;

EID: 84949024245     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.2729     Document Type: Article

References (53)

1. Billings LK, Florez JC., The genetics of type 2 diabetes: what have we learned from GWAS ? Ann N Y Acad Sci. 2010; 1212: 59-77.
2. Voight BF, Scott LJ, Steinthorsdottir V, et al., Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nat Genet. 2010; 42 (7): 579-89.
3. Holick MF., Vitamin D deficiency. N Engl J Med. 2007; 357 (3): 266-81.
4. Gonzalez-Molero I, Rojo-Martinez G, Morcillo S, et al., Vitamin D and incidence of diabetes: a prospective cohort study. Clin Nutr. 2012; 31 (4): 571-3.
5. Pittas AG, Lau J, Hu FB, Dawson-Hughes B., The role of vitamin D and calcium in type 2 diabetes. A systematic review and meta-analysis. J Clin Endocrinol Metab. 2007; 92 (6): 2017-29.
6. Pittas AG, Nelson J, Mitri J, et al., Plasma 25-hydroxyvitamin D and progression to diabetes in patients at risk for diabetes: an ancillary analyses in the Diabetes Prevention Program. Diabetes Care. 2012; 35 (3): 565-73.
7. Parildar H, Cigerli O, Unal AD, Gulmez O, Demirag NG., The impact of vitamin D replacement on glucose metabolism. Pak J Med Sci. 2013; 29 (6): 1311-4.
8. Naharci I, Bozoglu E, Kocak N, Doganci S, Doruk H, Serdar M., Effect of vitamin D on insulin sensitivity in elderly patients with impaired fasting glucose. Geriatr Gerontol Int. 2012; 12 (3): 454-60.
9. Nazarian S, St Peter JV, Boston RC, Jones SA, Mariash CN., Vitamin D3 supplementation improves insulin sensitivity in subjects with impaired fasting glucose. Transl Res. 2011; 158 (5): 276-81.
10. Pittas AG, Harris SS, Stark PC, Dawson-Hughes B., The effects of calcium and vitamin D supplementation on blood glucose and markers of inflammation in nondiabetic adults. Diabetes Care. 2007; 30 (4): 980-6.
11. von Hurst PR, Stonehouse W, Coad J., Vitamin D supplementation reduces insulin resistance in South Asian women living in New Zealand who are insulin resistant and vitamin D deficient-a randomised, placebo-controlled trial. Br J Nutr. 2010; 103 (4): 549-55.
12. DeFronzo RA, Gunnarsson R, Bjorkman O, Olsson M, Wahren J., Effects of insulin on peripheral and splanchnic glucose metabolism in noninsulin-dependent (type II) diabetes mellitus. J Clin Invest. 1985; 76 (1): 149-55.
13. DeFronzo RA, Tripathy D., Skeletal muscle insulin resistance is the primary defect in type 2 diabetes. Diabetes Care. 2009;32 Suppl 2: S157-63.
14. Shulman GI., Unraveling the cellular mechanism of insulin resistance in humans: new insights from magnetic resonance spectroscopy. Physiology (Bethesda). 2004; 19: 183-90.
15. Tahrani AA, Bailey CJ, Del Prato S, Barnett AH., Management of type 2 diabetes: new and future developments in treatment. Lancet. 2011; 378 (9786): 182-97.
16. Alvarez JA, Ashraf AP, Hunter GR, Gower BA., Serum 25-hydroxyvitamin D and parathyroid hormone are independent determinants of whole-body insulin sensitivity in women and may contribute to lower insulin sensitivity in African Americans. Am J Clin Nutr. 2010; 92 (6): 1344-9.
17. Chiu KC, Chu A, Go VL, Saad MF., Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction. Am J Clin Nutr. 2004; 79 (5): 820-5.
18. Chonchol M, Scragg R., 25-Hydroxyvitamin D, insulin resistance, and kidney function in the Third National Health and Nutrition Examination Survey. Kidney Int. 2007; 71 (2): 134-9.
19. Cheng Z, White MF., Targeting Forkhead box O1 from the concept to metabolic diseases: lessons from mouse models. Antioxid Redox Signal. 2011; 14 (4): 649-61.
20. Vogt PK, Jiang H, Aoki M., Triple layer control: phosphorylation, acetylation and ubiquitination of FOXO proteins. Cell Cycle. 2005; 4 (7): 908-13.
21. Essers MA, Weijzen S, de Vries-Smits AM, et al., FOXO transcription factor activation by oxidative stress mediated by the small GTPase Ral and JNK. EMBO J. 2004; 23 (24): 4802-12.
22. Wang MC, Bohmann D, Jasper H., JNK extends life span and limits growth by antagonizing cellular and organism-wide responses to insulin signaling. Cell. 2005; 121 (1): 115-25.
23. Feige JN, Lagouge M, Canto C, et al., Specific SIRT1 activation mimics low energy levels and protects against diet-induced metabolic disorders by enhancing fat oxidation. Cell Metab. 2008; 8 (5): 347-58.
24. Motta MC, Divecha N, Lemieux M, et al., Mammalian SIRT1 represses forkhead transcription factors. Cell. 2004; 116 (4): 551-63.
25. Cheng Z, Guo S, Copps K, et al., Foxo1 integrates insulin signaling with mitochondrial function in the liver. Nat Med. 2009; 15 (11): 1307-11.
26. Furuyama T, Kitayama K, Yamashita H, Mori N., Forkhead transcription factor FOXO1 (FKHR)-dependent induction of PDK4 gene expression in skeletal muscle during energy deprivation. Biochem J. 2003;375(Pt 2):365-71.
27. Kim YI, Lee FN, Choi WS, Lee S, Youn JH., Insulin regulation of skeletal muscle PDK4 mRNA expression is impaired in acute insulin-resistant states. Diabetes. 2006; 55 (8): 2311-7.
28. Jeoung NH, Harris RA., Pyruvate dehydrogenase kinase-4 deficiency lowers blood glucose and improves glucose tolerance in diet-induced obese mice. Am J Physiol Endocrinol Metab. 2008; 295 (1): E46-54.
29. Kamei Y, Miura S, Suzuki M, et al., Skeletal muscle FOXO1 (FKHR) transgenic mice have less skeletal muscle mass, down-regulated Type I (slow twitch/red muscle) fiber genes, and impaired glycemic control. J Biol Chem. 2004; 279 (39): 41114-23.
30. Kim JJ, Li P, Huntley J, Chang JP, Arden KC, Olefsky JM., FoxO1 haploinsufficiency protects against high-fat diet-induced insulin resistance with enhanced peroxisome proliferator-activated receptor gamma activation in adipose tissue. Diabetes. 2009; 58 (6): 1275-82.
31. Waddell DS, Baehr LM, van den Brandt J, et al., The glucocorticoid receptor and FOXO1 synergistically activate the skeletal muscle atrophy-associated MuRF1 gene. Am J Physiol Endocrinol Metab. 2008; 295 (4): E785-97.
32. Yamazaki Y, Kamei Y, Sugita S, et al., The cathepsin L gene is a direct target of FOXO1 in skeletal muscle. Biochem J. 2010; 427 (1): 171-8.
33. O'Neill BT, Lauritzen HP, Hirshman MF, Smyth G, Goodyear LJ, Kahn CR., Differential role of insulin/IGF-1 receptor signaling in muscle growth and glucose homeostasis. Cell Rep. 2015; 11 (8): 1220-35.
34. Chen S, Law CS, Grigsby CL, et al., Cardiomyocyte-specific deletion of the vitamin D receptor gene results in cardiac hypertrophy. Circulation. 2011; 124 (17): 1838-47.
35. Li YC, Amling M, Pirro AE, et al., Normalization of mineral ion homeostasis by dietary means prevents hyperparathyroidism, rickets, and osteomalacia, but not alopecia in vitamin D receptor-ablated mice. Endocrinology. 1998; 139 (10): 4391-6.
36. Bothe GW, Haspel JA, Smith CL, Wiener HH, Burden SJ., Selective expression of Cre recombinase in skeletal muscle fibers. Genesis. 2000; 26 (2): 165-6.
37. Wamhoff BR, Sinha S, Owens GK., Conditional mouse models to study developmental and pathophysiological gene function in muscle. Handb Exp Pharmacol. 2007;(178): 441-68.
38. Xie P, Guo S, Fan Y, Zhang H, Gu D, Li H. Atrogin-1/MAFbx enhances simulated ischemia/reperfusion-induced apoptosis in cardiomyocytes through degradation of MAPK phosphatase-1 and sustained JNK activation. J Biol Chem. 2009; 284 (9): 5488-96.
39. Zhang Y, Leung DY, Richers BN, et al., Vitamin D inhibits monocyte/macrophage proinflammatory cytokine production by targeting MAPK phosphatase-1. J Immunol. 2012; 188 (5): 2127-35.
40. Meriane M, Roux P, Primig M, Fort P, Gauthier-Rouviere C., Critical activities of Rac1 and Cdc42Hs in skeletal myogenesis: antagonistic effects of JNK and p38 pathways. Mol Biol Cell. 2000; 11 (8): 2513-28.
41. Crossland H, Constantin-Teodosiu D, Gardiner SM, Constantin D, Greenhaff PL., A potential role for Akt/FOXO signalling in both protein loss and the impairment of muscle carbohydrate oxidation during sepsis in rodent skeletal muscle. J Physiol. 2008;586(Pt 22): 5589-600.
42. Ceglia L, Niramitmahapanya S, da Silva Morais M, et al., A randomized study on the effect of vitamin D(3) supplementation on skeletal muscle morphology and vitamin D receptor concentration in older women. J Clin Endocrinol Metab. 2013; 98 (12): E1927-35.
43. Srikuea R, Zhang X, Park-Sarge OK, Esser KA., VDR and CYP27B1 are expressed in C2C12 cells and regenerating skeletal muscle: potential role in suppression of myoblast proliferation. Am J Physiol Cell Physiol. 2012; 303 (4): C396-405.
44. Chemello F, Bean C, Cancellara P, Laveder P, Reggiani C, Lanfranchi G., Microgenomic analyses in skeletal muscle: expression signatures of individual fast and slow myofibers. PLoS One. 2011; 6 (2): e16807.
45. Gross DN, van den Heuvel AP, Birnbaum MJ., The role of FoxO in the regulation of metabolism. Oncogene. 2008; 27 (16): 2320-36.
46. An BS, Tavera-Mendoza LE, Dimitrov V, et al., Stimulation of Sirt1-regulated FoxO protein function by the ligand-bound vitamin D receptor. Mol Cell Biol. 2010; 30 (20): 4890-900.
47. Eelen G, Verlinden L, Meyer MB, et al., 1,25-Dihydroxyvitamin D3 and the aging-related forkhead box O and sestrin proteins in osteoblasts. J Steroid Biochem Mol Biol. 2013; 136: 112-9.
48. Perdiguero E, Ruiz-Bonilla V, Serrano AL, Munoz-Canoves P., Genetic deficiency of p38alpha reveals its critical role in myoblast cell cycle exit: the p38alpha-JNK connection. Cell Cycle. 2007; 6 (11): 1298-303.
49. Chiacchiera F, Matrone A, Ferrari E, et al., p38alpha blockade inhibits colorectal cancer growth in vivo by inducing a switch from HIF1alpha- to FoxO-dependent transcription. Cell Death Differ. 2009; 16 (9): 1203-14.
50. Qin W, Pan J, Wu Y, Bauman WA, Cardozo C., Protection against dexamethasone-induced muscle atrophy is related to modulation by testosterone of FOXO1 and PGC-1alpha. Biochem Biophys Res Commun. 2010;403(3-4): 473-8.
51. Zeitz U, Weber K, Soegiarto DW, Wolf E, Balling R, Erben RG., Impaired insulin secretory capacity in mice lacking a functional vitamin D receptor. FASEB J. 2003;17(3):509-11.
52. Bula CM, Huhtakangas J, Olivera C, Bishop JE, Norman AW, Henry HL., Presence of a truncated form of the vitamin D receptor (VDR) in a strain of VDR-knockout mice. Endocrinology. 2005; 146 (12): 5581-6.
53. Norman AW, Frankel JB, Heldt AM, Grodsky GM. Vitamin D deficiency inhibits pancreatic secretion of insulin. Science. 1980; 209 (4458): 823-5.